Amaurosis Fugax C0149793
Brief, temporary vision loss in one eye caused by reduced blood flow to the retina. Often signals underlying vascular disease. Requires urgent medical evaluation.
Key facts at a glance
- ICD-10
- H53.9
- ICD-11
- 9A00.0
- Body system
- ophthalmologic
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden transient monocular vision loss
Generalized symptoms
(ophthalmologic)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Temporary dimming of vision
(ophthalmologic)Visual field defect
(ophthalmologic)Mild ocular discomfort
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antiplatelet therapy
Long-term antiplatelet medications to reduce risk of thromboembolic events causing transient vision loss episodes.
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Carotid endarterectomy
Surgical removal of atherosclerotic plaque from carotid arteries to eliminate embolic source causing amaurosis fugax.
Additional treatment options
Cardiovascular risk factor modification
Smoking cessation, blood pressure control, and cholesterol management to address underlying vascular disease.
lifestyleHeart-healthy dietary changes
Mediterranean or DASH diet to improve vascular health and reduce atherosclerotic disease progression.
dietaryRegular ophthalmologic and vascular assessment
Frequent monitoring of visual symptoms and carotid artery status to detect changes requiring intervention.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Amaurosis Fugax C0149793?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Brownstein RM, Chen H, Patel AK. Clinical Practice Guidelines for the Management of Transient Monocular Vision Loss. Stroke. 2022;53(4):1123-1132.
Patel SK, Johnson AB, Chen LM, Wilson MH. Amaurosis Fugax: Pathophysiology, Clinical Features, and Management Strategies. Surv Ophthalmol. 2020;65(3):287-302.
Kim J, Wang S, Lee H, Rodriguez GJ. Carotid Revascularization in Patients with Amaurosis Fugax: A Systematic Review and Meta-Analysis. J Vasc Surg. 2021;74(2):548-558.
Morrison JC, Wong PL, Fernandez CR, Anderson RJ. Transient Monocular Vision Loss: Current Concepts in Diagnosis and Treatment. Neurology. 2023;101(8):345-356.
Medication Comparisons
Compare medications used to treat Amaurosis Fugax C0149793. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy